Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 8/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22771095 | 1.00 | ACACB (0.47) | ACACBRORCNAMPTDRD2MBTD1 | |
| SCHEMBL24507851 | 0.84 | RORC (0.51) | ACACBRORCNAMPTDRD2 | |
| SCHEMBL22777252 | 0.83 | MBTD1 (0.49) | MBTD1L3MBTL3SIRT2 | |
| SCHEMBL22771132 | 0.83 | PRMT5 (0.43) | ACACBRORCNAMPT | |
| SCHEMBL30233505 | 0.83 | PRMT5 (0.43) | ACACBRORCNAMPT | |
| SCHEMBL15934192 | 0.81 | NAMPT (0.49) | ACACBNAMPTDRD2 | |
| SCHEMBL22771128 | 0.80 | MBTD1 (0.40) | RORCMBTD1L3MBTL3SIRT2 | |
| SCHEMBL22771245 | 0.79 | MBTD1 (0.49) | DRD2MBTD1L3MBTL3SIRT2 | |
| SCHEMBL24571611 | 0.77 | MBTD1 (0.52) | NAMPTMBTD1L3MBTL3 | |
| SCHEMBL31619960 | 0.77 | MBTD1 (0.52) | NAMPTMBTD1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4146282-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20220315537-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | IDO2, IDO1, BCR | ACACB 289/4885RORC 1177/4885NAMPT 3502/4885 |
| US-20220315537-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | CCNB1, CCNB2, MUS81 | ACACB 400/4885RORC 4501/4885NAMPT 3372/4885 |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | SERPINB1, ELANE, CELA1 | ACACB 2551/4885RORC 4140/4885NAMPT 1903/4885 |
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BCL6, CLTB, MET | ACACB 914/4885RORC 1818/4885NAMPT 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.